Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Nasopharyngeal Carcinoma Clinical Trials

5 recruiting trials for Nasopharyngeal Carcinoma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
5
Total Trials
5
Recruiting Now
0
Phase 3 Trials
5
Sponsors

Recruiting Trials

RECRUITINGNCT06852638

CD70-targeted immunoPET Imaging of Malignant Cancers

This study aims to establish and optimize the cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and...

Sponsor: RenJi HospitalEnrolling: 3001 location
RECRUITINGPhase 2NCT05431764

Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma

In this exploratory clinical trial, patients with newly diagnosed distant metastatic nasopharyngeal carcinoma were treated with gemcitabine+ cisplatin+PD-1 inhibitor regimen...

Sponsor: Sun Yat-sen UniversityEnrolling: 381 location
RECRUITINGPhase 2NCT04813705

18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma

The purpose of this study is to explore whether 18F-FDG PET/CT guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.

Sponsor: Taizhou HospitalEnrolling: 934 locations
RECRUITINGNCT06321939

Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma

The investigators aim to explore a new EBV DNA surveillance method with both high sensitivity and specificity in nasopharyngeal carcinoma (NPC) patients. the investigators aim to...

Sponsor: Hunan Cancer HospitalEnrolling: 501 location
RECRUITINGNCT05994170

Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma

To evaluate the long-term local control, survival rate, acute and late radiation related toxicities, quality of life after reducing high risk primary tumor clinical target volumes...

Sponsor: Zhongshan People's Hospital, Guangdong, ChinaEnrolling: 4541 location